Full vial shown · package appearance may vary by batch24/7 Customer Support
Lab tested for purity & quality
Ships from Canada within 24 hours
At Puffin Peptides, we work with an established Canadian manufacturer and handle packaging and fulfilment here in Canada. Keeping the process close to home gives us better visibility into quality, consistency, packaging, and the batches moving through our catalogue.
That means clearer product information, accessible batch documentation, responsive local support, and a more dependable ordering experience from checkout to delivery.
Our focus is simple: well-made research products, straightforward information, and reliable Canadian service.
Built to target metabolism from three different angles, Retatrutide is an advanced peptide that acts on pathways linked to hunger, blood sugar regulation, and energy use. Its triple-action approach may support appetite control, improved metabolic function, and substantial fat loss—making it one of the most exciting peptides being studied for body composition and weight management.
RETATRUTIDE is supplied as 30 mg of lyophilized powder in a sealed glass vial for laboratory research. Confirm the selected vial and batch details before preparation.
Retatrutide is a synthetic 39-amino-acid peptide engineered as a unimolecular agonist of the GIP, GLP-1 and glucagon receptors.
This 30 mg vial opens with 3 mL BAC water.
The default easy rule is 1 mg = 10 units on a U-100 syringe. Changing the water amount updates that relationship automatically.
Want to measure an mg amount?Open the reconstitution calculatorStore unprepared vials in a cool, dry place away from heat and moisture.
Refrigerate prepared vials between 2–8°C.
Avoid repeated freeze-thaw cycles.
A clear, quick look at what RETATRUTIDE is, how it works, and why it is being studied.
Retatrutide is being studied for three big weight-loss challenges: constant hunger, stubborn cravings, and how the body uses energy. Plain English: less hunger coming in, more energy being used, and an easier path toward losing weight.
Retatrutide is an investigational single molecule that agonizes GIP, GLP-1 and glucagon receptors. A randomized phase 2 obesity trial found dose-dependent reductions in body weight over 48 weeks; the contribution of each receptor pathway to the overall effect remains an active research question. [1]
Think about finishing a meal and feeling genuinely satisfied instead of searching the kitchen again an hour later. Retatrutide works with signals that may help smaller meals feel filling and keep that satisfied feeling around longer.
GLP-1 and GIP are nutrient-responsive incretin pathways involved in insulin secretion and appetite signalling, while GLP-1 activity can also slow gastric emptying. “Fuller longer” is useful plain English, but not every subjective appetite experience has been independently validated as a retatrutide endpoint. [1]
That is a huge part of its appeal. When hunger and fullness signals are quieter, the urge to graze or keep thinking about food may become easier to ignore—what many people call less ‘food noise.’
Human retatrutide trials establish body-weight and metabolic outcomes more strongly than every specific craving or snacking behaviour. Its incretin-receptor activity provides a plausible appetite-related mechanism, but terms such as “food noise” should remain more cautious than the clinical evidence. [1]
Not literally, but the comparison is useful. Its glucagon signal may encourage the body to use more energy and stored fuel—like gently turning up the thermostat while appetite support helps reduce what is coming in.
The glucagon-receptor component is scientifically important because glucagon signalling can influence hepatic metabolism and energy expenditure. “Furnace” is only an analogy; trials do not establish that retatrutide simply raises calorie burn independently of food intake and other metabolic effects. [1]
Each has a job: GLP-1 supports fullness, GIP helps the body respond to food, and glucagon may increase energy use. Together they approach weight loss from three directions instead of relying on appetite control alone.
Retatrutide combines agonism at GIPR, GLP-1R and GCGR to integrate incretin effects on glucose/appetite with glucagon-receptor biology related to substrate use and energy balance. The optimal balance among those signals is still being studied. [1]
Semaglutide uses one main signal, Tirzepatide uses two, and Retatrutide uses three. The easy way to remember it: appetite support, broader appetite support, then appetite support plus the metabolism-focused ‘furnace’ signal.
Semaglutide is a GLP-1 receptor agonist, tirzepatide activates GIP and GLP-1 receptors, and retatrutide adds glucagon-receptor agonism. Cross-trial percentages should not be treated as head-to-head proof because populations, durations and protocols differ. [1]
It is not magic. Its appeal is making the hardest parts of weight loss feel more manageable: smaller portions when you feel full, fewer snacks when cravings are quieter, and better consistency when hunger is not always winning.
Clinical trials evaluate retatrutide within defined protocols and populations; they do not establish that one compound replaces nutrition, activity, sleep or broader medical care. Body-weight change remains a multi-factor outcome. [1]
It brings appetite control, longer-lasting fullness, and increased energy use into one compound. That combination has produced standout weight-loss results in clinical research and is why Reta is watched so closely.
Interest is driven by both its triple-receptor pharmacology and the magnitude of weight reduction reported in phase 2 human research. It remains investigational, so promising trial results are not the same as a completed long-term evidence base for every population or outcome. [1]
This product is offered for laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement or substitute for an approved product.
Confirm the selected vial and BAC-water amount, enter the target amount, then follow the preparation and storage steps.
The selected strength automatically opens with the easy starting rule of 1 mg = 10 units.
RETATRUTIDE · 30 mg selected
Easy rule: 1 mg = 10 units · Every 10 units = 1 mg
This calculator converts the values entered. It does not choose an amount.
This 30 mg vial opens with 3 mL of BAC water, creating the easy starting rule of 1 mg = 10 units.
If the water amount is changed above, use the updated easy rule shown by the calculator.
Do not shake the vialSlowly add the water down the inside wall of the vial, then gently swirl until fully dissolved.
Prepared vialsRefrigerate at 2–8°C
Unprepared vialsKeep cool and dry, away from heat, moisture, and direct sunlight
Every order is prepared and packed in Canada with care, accuracy, and attention to detail. In-stock orders are checked and packed within 24 hours, then shipped with Canada Post. Tracking is sent after the parcel’s first carrier scan.
2 customer reviews
Reviews are checked before publication. Your email is never displayed.
Nice site and helpful chat bot. I’ll be back again.
I can’t believe it but I’ve lost 30lb. It’s been 3 months and felt compelled to write a review. I know it’s not Puffin I have to thank but their site came up in google and brought me here. Thank youuuuuu! <3
Products in the same research area, each with its own pathway, evidence level and selectable strengths.
16% off
15% offPuffin Pick
Only logged in customers who have purchased this product may leave a review.
Hi! I’m Ask Puffin. I can explain peptides in plain language and help with products, prices, stock, shipping, and site questions. What can I help with?
Kimmy Sonn (verified owner) –
I can’t believe it but I’ve lost 30lb. It’s been 3 months and felt compelled to write a review. I know it’s not Puffin I have to thank but their site came up in google and brought me here. Thank youuuuuu! <3